Shao SC, Chang KC, Hung MJ, et al. - In this retrospective cohort study utilizing Chang Gung Research Database (a multi-institutional electronic medical records database) in Taiwan, researchers compared a composite of cardiovascular death, myocardial infarction, ischemic stroke and heart failure among type 2 diabetes patients newly receiving dapagliflozin vs empagliflozin. With a mean age of 58.9 (SD 11.8) years, a total of 12,681 new sodium–glucose co-transporter 2 inhibitor users, including 43.9% females and 45.8% new dapagliflozin users, were identified. Overall 10,442 person-years of dapagliflozin use and 12,096 person-years of empagliflozin use were included. A similar risk of cardiovascular events was evident between dapagliflozin and empagliflozin new users, but dapagliflozin may be better than empagliflozin in terms of reducing heart failure in T2D patients.